.

Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
McKesson
Fish and Richardson
Chubb
Dow
Fuji
Baxter
Johnson and Johnson
Queensland Health
Julphar

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,939,502

« Back to Dashboard

Which drugs does patent 7,939,502 protect, and when does it expire?


Patent 7,939,502 protects BETHKIS and is included in one NDA. There has been one Paragraph IV challenge on Bethkis.

This patent has thirty-four patent family members in twenty-six countries.

Summary for Patent: 7,939,502

Title:Optimised formulation of tobramycin for aerosolization
Abstract: The invention provides a tobramycin formulation for delivery by aerosolization in the form of additive-free, isotonic solution whose pH has been optimised to ensure adequate shelf-life at room temperature. Said formulation can be advantageously used for the treatment and prophylaxis of acute and chronic endobronchial infections, in particular those caused by the bacterium Pseudomonas aeruginosa associated to lung diseases such as cystic fibrosis.
Inventor(s): Malvolti; Chiara (Parma, IT), Garzia; Raffaella (Parma, IT)
Assignee: Chiesi Farmaceutici S.p.A. (Parma, IT)
Application Number:12/642,336
Patent Claim Types:
see list of patent claims
Use; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Chiesi Usa IncBETHKIStobramycinSOLUTION;INHALATION201820-001Oct 12, 2012RXYesYes► Subscribe► Subscribe► SubscribeMANAGEMENT OF CYSTIC FIBROSIS PATIENTS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,939,502

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
01116071Jul 02, 2001

Non-Orange Book Patents for Patent: 7,939,502

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,987,094Optimized formulation of tobramycin for aerosolization► Subscribe
8,168,598Optimised formulation of tobramycin for aerosolization► Subscribe
7,696,178Optimised formulation of tobramycin for aerosolization► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,939,502

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Turkey200401980► Subscribe
TunisiaSN03149► Subscribe
Slovakia285806► Subscribe
Slovakia16432003► Subscribe
SloveniaEP1273292► Subscribe
Portugal1273292► Subscribe
Poland202598► Subscribe
Poland367139► Subscribe
South Korea100910888► Subscribe
South Korea20040018403► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Chubb
Dow
Johnson and Johnson
Harvard Business School
Farmers Insurance
Federal Trade Commission
Teva
McKinsey
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot